# IMpassion 031 (NCT03197935)

> A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03197935
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Triple-negative Breast Cancer
- Interventions: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody; Placebo; Nab-paclitaxel; Doxorubicin; Cyclophosphamide; Filgrastim; Pegfilgrastim
- Enrollment: 333
- Primary outcome: Number of Participants With Pathologic Complete Response (pCR) Using American Joint Committee on Cancer (AJCC) Staging System in ITT Population
- Primary outcome: Number of Participants With pCR in Subpopulation With PD-L1-Positive Tumor Status (Tumor-infiltrating Immune Cell [IC] 1/2/3) Using AJCC Staging System

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 10
- Podcasts: 9
- X threads: 8

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=impassion-031-nct03197935

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03197935", "email": "<work email>"}; the inbox owner confirms by the emailed link.